X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/lipocine-announces-favorable-regulatory-pathway-on-oral-lpcn-1154-for-post-partum-depression-ppd-301624932.html
https://endpts.com/blasted-by-phiii-failure-a-struggling-sage-axes-340-staffers-and-bunkers-down-to-survive-the-storm/
http://www.pharmafile.com/news/545912/sage-therapeutics-halve-its-total-workforce-radical-cost-cutting-move
https://www.biopharmadive.com/news/sage-zulresso-slow-start-focus-depression-data-mountain/567234/
https://www.fiercepharma.com/marketing/soft-launch-sage-strategy-for-postpartum-depression-drug-zulresso-keys-awareness-and
https://www.in-pharmatechnologist.com/Article/2019/03/25/FDA-approves-first-drug-specifically-for-postpartum-depression
https://www.nih.gov/news-events/news-releases/bench-bedside-nimh-research-leads-brexanolone-first-ever-drug-specifically-postpartum-depression
http://www.pmlive.com/pharma_news/sage_raises_$575m_ahead_of_fda_review_date_for_zulresso_1279699
https://www.businesswire.com/news/home/20181120005168/en/Sage-Therapeutics-Receives-Notification-PDUFA-Extension-ZULRESSO%E2%84%A2
https://www.biopharmadive.com/news/sage-depression-drug-to-cost-between-20k-and-35k-if-approved/541613/
https://endpts.com/sage-appears-set-for-a-breakthrough-fda-ok-on-postpartum-depression-drug-but-whos-going-to-use-it/
https://www.reuters.com/article/us-sage-fda/fda-panel-recommends-sages-postpartum-depression-treatment-idUSKCN1N72EU
https://endpts.com/fda-staff-suggest-safety-profile-of-sage-postpartum-depression-drug-disqualify-it-from-at-home-infusions/
https://endpts.com/sage-files-for-an-approval-for-its-breakthrough-therapy-for-postpartum-depression/
https://www.cnbc.com/2018/03/28/sage-therapeutics-ceo-well-price-postpartum-drug-fairly.html
https://seekingalpha.com/article/4137580-sages-antidepressant-franchise-make-acquisition-target
https://www.biospace.com/article/exclusive-sage-therapeutics-looks-to-file-nda-for-postpartum-depression-treatment-later-this-year/
https://www.cnbc.com/2017/11/10/sage-pharmaceuticals-stock-up-after-successful-trials-for-postpartum-depression-drug.html
http://www.reuters.com/article/us-sage-trials/sages-seizure-drug-fails-key-trial-shares-slump-idUSKCN1BN14N
http://www.fiercebiotech.com/biotech/sage-therapeutics-fuels-and-then-dampens-its-own-m-a-rumors
http://www.fiercebiotech.com/biotech/sage-soars-small-post-partum-depression-study-results
Market Place
Share 
